Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 5 bp deletion in exon 8 and Insertion of the selection cassette in exon 8.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-FBXO11, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FBXO11 also known as F-box only protein 11 is a member of the F-box protein family which are characterized by an F-box motif a sequence of approximately 40 amino acids. It has an approximate mass of 114 kDa. FBXO11 participates in the ubiquitin-proteasome system by acting as a substrate-recognition component of SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complexes. The protein is expressed in various tissues throughout the body including lung liver and skin.
Biological function summary
FBXO11 is involved in protein degradation and regulation of the cell cycle. It serves as an important component of the SCF ubiquitin ligase complex where it binds to specific substrates marking them for proteasomal degradation. FBXO11 plays an important role in cellular processes such as DNA damage response and cell growth regulation. By targeting specific proteins for degradation it regulates protein stability which is important for normal cellular proliferation.
Pathways
FBXO11 is critical in the TGF-beta signaling pathway and the apoptosis pathway. In the TGF-beta signaling pathway FBXO11 regulates the stability of inhibitory SMAD proteins like SMAD7 by targeting them for proteasomal degradation. This regulation impacts cellular responses to TGF-beta influencing processes like cell differentiation and immune responses. In apoptosis FBXO11 interacts with other proteins like BCL2 to influence cell survival and programmed cell death.
FBXO11 plays a role in specific types of cancer and developmental disorders. Mutations or dysregulation of FBXO11 have identified links to diffuse large B-cell lymphoma due to its ability to affect the degradation of BCL6— a transcriptional repressor involved in the development and growth of this cancer. In developmental disorders FBXO11 mutations have associations with conditions like the oculo-facio-cardio-dental syndrome illustrating its importance in normal developmental processes.
